Calcimedica announces first patient enrolled in phase 2 kourage trial of auxora™ in severe acute kidney injury (aki)

Development of auxora in aki is supported by both clinical and pre-clinical evidence topline data expected in 2025 la jolla, calif. , july 9, 2024 /prnewswire/ -- calcimedica inc. ("calcimedica" or the "company") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that the first patient has been dosed in kourage, the company's phase 2 trial evaluating auxora™ for the treatment of severe acute kidney injury (aki) with associated acute hypoxemic respiratory failure (ahrf).
CALC Ratings Summary
CALC Quant Ranking